California State Teachers Retirement System Purchases 10,531,698 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• California State Teachers Retirement System dramatically increased its Halozyme Therapeutics stake by purchasing 10.53 million shares in the second quarter, bringing its ownership to 10.67 million shares, or approximately 9.4% of the company. Institutional investors and hedge funds collectively own 97.79% of HALO.
• Halozyme reported strong quarterly results, with revenue rising 47.7% year over year to $481 million and EPS of $2.28, exceeding analysts’ $1.79 estimate. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analyst sentiment is generally positive, with nine Buy ratings, three Holds and one Sell, producing a consensus “Moderate Buy” rating. However, insiders have sold 72,478 shares worth approximately $7.37 million over the past three months.

California State Teachers Retirement System lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 7,724.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,668,044 shares of the biopharmaceutical company's stock after acquiring an additional 10,531,698 shares during the period. California State Teachers Retirement System owned approximately 9.40% of Halozyme Therapeutics worth $834,988,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. HB Wealth Management LLC grew its stake in Halozyme Therapeutics by 281.9% during the second quarter. HB Wealth Management LLC now owns 14,202 shares of the biopharmaceutical company's stock worth $1,112,000 after purchasing an additional 10,483 shares during the period. AlphaGrep UK Ltd acquired a new position in Halozyme Therapeutics in the second quarter valued at approximately $340,000. BAM Wealth Management LLC boosted its holdings in shares of Halozyme Therapeutics by 37.7% during the 2nd quarter. BAM Wealth Management LLC now owns 6,175 shares of the biopharmaceutical company's stock worth $483,000 after buying an additional 1,691 shares in the last quarter. denkapparat Operations GmbH bought a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $390,000. Finally, AXQ Capital LP grew its position in shares of Halozyme Therapeutics by 111.8% during the 2nd quarter. AXQ Capital LP now owns 30,831 shares of the biopharmaceutical company's stock worth $2,413,000 after buying an additional 16,277 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $107.20 on Monday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $111.15. The business has a 50 day moving average price of $93.73 and a 200-day moving average price of $77.01. The company has a market cap of $12.17 billion, a price-to-earnings ratio of 32.00, a P/E/G ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. During the same period last year, the business earned $1.54 EPS. Halozyme Therapeutics's quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 31st. Leerink Partners raised shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. Finally, Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $91.20.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 72,478 shares of company stock valued at $7,370,004. Corporate insiders own 2.50% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.